California Pharma Co. Tests Breakthrough Cancer Drug, Cuts Death Risk 60%

1. Cori Fisher wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee. 
2. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 
3. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

On May 31, 2026, Revolution Medicines Inc. (RVMD:NASDAQ) announced detailed results from its global, randomized Phase 3 RASolute 302 clinical trial that evaluated daraxonrasib for patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC). This potential new oncology drug is an oral RAS(ON) multi-selective inhibitor intended as a therapy for RAS-addicted cancers.

RAS is a key growth control switch in human cells and is the primary oncogenic driver of PDAC, which is typically characterized by excessive RAS(ON) signaling in tumors with or without a mutant allele of RAS. Daraxonrasib is the first investigational agent in its class of RAS(ON) multi-selective inhibitors. The randomized Phase 3 trial tested once-daily oral daraxonrasib and found "unprecedented improvements in overall survival and progression-free survival rates compared to standard therapies," according to the press release. The company reported that all primary and key secondary endpoints of the trial were met, while the drug exhibited a manageable safety profile and significantly delayed deterioration in cancer-related pain and overall quality of life compared to those treated with standard chemotherapy.

Mark A. Goldsmith, M.D., Ph.D., and CEO and Chairman of Revolution, said, "The data from the Phase 3 RASolute 302 trial clearly validate our pioneering, science-driven approach and add to the growing body of evidence underscoring the broad potential of RAS(ON) inhibition that we are testing across pancreatic cancer and other RAS-driven cancers." Dr. Goldsmith continued, "Daraxonrasib significantly elevates the survival bar in the treatment of one of the deadliest human cancers, while better preserving quality of life compared to chemotherapy. In this trial, daraxonrasib redefined treatment expectations in previously treated metastatic pancreatic cancer by reducing the risk of death by 60% and increasing median overall survival to more than one year, a result not previously reported in any Phase 3 clinical trial in any line of therapy for this disease. These striking results firmly support daraxonrasib as the new standard of care for patients with previously treated metastatic pancreatic cancer, and usher in a new era of RAS-targeted therapy for patients living with this disease."

Brian M. Wolpin, M.D., M.P.H., director of the Hale Family Center for Pancreatic Cancer Research at Dana-Farber Cancer Institute, professor of medicine at Harvard Medical School, and principal investigator for the RASolute 302 trial, also weighed in. Dr. Wolpin said, "These results from the Phase 3 RASolute 302 trial of daraxonrasib represent a major milestone for patients facing metastatic pancreatic cancer. For many patients, second-line chemotherapy provides modest benefits, and new treatments delivering more durable tumor control have been urgently needed. In this global randomized trial, daraxonrasib, an oral RAS(ON) inhibitor, doubled median overall survival compared to standard of care chemotherapy for patients with previously treated metastatic pancreatic cancer. Importantly, this survival benefit was achieved with a generally manageable safety profile, highlighted by the low rate of treatment discontinuation due to treatment-related side effects."

With optimism, Dr. Wolpin anticipated future results, saying, "These results will change how scientists, clinicians, and patients think about treatment for pancreatic cancer, and support a new paradigm where RAS(ON) inhibition enters standard of care for patients with previously treated metastatic pancreatic adenocarcinoma."

Revolution is a late-stage oncology pharma testing company headquartered in Redwood City, California. Its flagship drug, daraxonrasib, is designed to target cancers driven by a broad range of common RAS genotypes, including PDAC, non-small cell lung cancer (NSCLC), and colorectal cancer. In addition to the RASolute 302 trial, daraxonrasib is being evaluated in three other global Phase 3 registrational trials, including in patients with PDAC and metastatic RAS mutant NSCLC.

Oncology Sector Demand Growing

In February 2026, Iqvia discussed the global pharma market projection for 2026, noting that total drug usage is expected to surpass four trillion doses daily by 2030. They wrote, "The largest drivers of medicine spending growth through the next five years will continue to be the use in developed markets of innovative therapeutics, especially in oncology, immunology, diabetes, and obesity."

Pharma sector funding fell between 2024 and 2025, according to a March 26, 2026, article for Fierce Biotech by Nick Paul Taylor.  He wrote that pharma funding had fallen from 2024 but noted that, "2025 was still the third-best year of the past decade. Similarly, overall funding was well above the pre-pandemic norm and only topped by 2020, 2021, and 2024."

The global cancer treatment sector, unfortunately, shows no signs of shrinking. A March 26, 2026, article by Kinjel Shah for Yahoo Finance claimed that cancer incidences were rising. He quoted the American Cancer Society as expecting 2.1 million new cancer cases and over 626,000 cancer-related deaths in 2026. However, technology is ever-evolving to keep up with the disease.

Shah wrote, "Emerging technologies such as genomic sequencing, artificial intelligence, and machine learning are accelerating biomarker discovery, enhancing patient stratification, and enabling earlier and more accurate diagnoses. While a universal cure remains out of reach, consistent improvements in survival rates and patient outcomes across multiple cancer types highlight the tangible benefits of these advances, particularly when combined with earlier detection and intervention."

This innovation comes at a price. In February 2026, Keith Speights wrote an article for The Motley Fool discussing rising care costs, stating that cancer treatments in the U.S. cost roughly US$200 billion in 2020 but are expected to increase to more than US$245 billion by 2030.

BCG talked about trends biopharma companies need to be aware of in 2026 in order to stay competitive, saying, "Near term, companies need to continue to innovate to decrease the complexity and cost of these therapies, and governments can find ways to incentivize and pay for them. The longer-term challenge for companies is to factor operational and economic considerations into R&D decision making earlier, ensuring that trial designs match real-world usage, indication sequences match opportunity, and endpoints enable market access."

Company a "Favorite" Among Analysts

Robert Driscoll of Wedbush gave Streetwise Reports a quote on the company on June 1, 2026, saying: "I'd say we already knew from a press release that the overall survival data were positive, but the ASCO presentation confirmed clear, consistent efficacy across all patients, with no new safety signals — 'no holes in the data'. And we see significant momentum continuing for the drug as RVMD prepares to file for approval, with its access program already demonstrating robust demand."

Also on June 1, Equity Analyst Faisal Khurshid at Jeffries said, "With pot'l approval coming soon (we think July/Aug), RVMD remains one of our favorite names." Khurshid continued, " We think there may be a path for RVMD to get 1L on the label simultaneously w/ initial approval in 2L . . . co. did not outright dismiss this possibility, but emphasized scope of label ultimately up to FDA."

Jeffries gave Revolution a "Buy" rating, with a US$185 price target.

LifeSci Capital's Charles Zhu, Ph.D., was even more optimistic in his June 1 research report, giving the company an "Outperform" rating, with a price target of US$263.00. Dr. Zhu said, " The results were universally positive, and the enthusiasm surrounding RASolute 302 was clear."

As a note, Robert Langreth for Bloomberg pointed out one specific concern with the data on May 31, 2026, writing: "Median duration of treatment was 6.2 months, but we think this could be longer in real-world practice. RASolute 302 did not allow treatment beyond PD, although it is formally allowed in subsequent protocols, and physician feedback has consistently reflected an openness to treating beyond progression. Thus, we expect the real-world duration of treatment to be longer than reported here."

Sean McCutcheon, Ph.D., of Raymond James gave the company a "Strong Buy" rating on May 31, 2026, noting that "the progression-free survival results were strong" and arguing that "overall survival rates are a home run and are consistent across all prespecified subgroups."

A Pipeline Moving Fast

The company's investor presentation shows that Revolution has no plans to let these results stagnate and has already laid out the next steps. First, the company intends to provide eligible patients with this treatment option as soon as possible, with FDA-cleared Earl Access Program operations accessible to U.S.-licensed physicians on behalf of eligible patients. Next, the company is advancing multiple components of NDA through rolling submissions and sequential filings planned for international regulatory authorities.

With core operations and networks established in the U.S., Revolution is launching its representative team to access priority international markets across a range of oncology builds and launches.

Ownership & Share Information¹

Revolution Medicines Inc. has a market cap of US$34.80 billion, with 212.60 million shares outstanding. The company's 52-week range is US$34.00-US$266.50.

Institutions own 95.35% of shares, while Management & Insiders own 1.89%. The remaining 2.76% of shares are held by Retail.